Onco360 Appoints New President & CEO

October 27, 2014

Onco360 Appoints New President & CEO

New York – October 27, 2014 – Onco360, one of the nation’s largest independent providers of oncology pharmacy services, today announced that Paul Jardina has been named President and Chief Executive Officer.

Mr. Jardina has more than 20 years of healthcare industry experience as an executive in oncology and physician services. Most recently he served as President and CEO of U.S. Physiatry, a physician services company focused on physical medicine and rehabilitation in the post-acute continuum. Mr. Jardina has served in various leadership positions for U.S. Oncology (now McKesson Specialty Health), leading key business lines, including oncology specialty pharmacy, drug distribution, and radiation and imaging. In his role at U.S. Oncology, Mr. Jardina was instrumental in the development and growth of the company’s pharmaceutical service lines and its transition to an open market provider of oncology pharmaceutical services.

“Onco360 is a clear leader in oncology pharmacy care, with growing scale and the unique ability to service the localized needs of community- and hospital based-oncologists across the country,” said Mr. Jardina.  “I am honored to join the Company at this time of tremendous opportunity, and have already begun working with the talented team at Onco360 to further leverage Onco360’s robust care platform in order to provide even more patients with the best oncology care possible. I am excited to position the Company for its next phase of growth and development.”

Greg Weishar, CEO of PharMerica, a significant investor in Onco360, said, “We are confident that Paul is the right leader to take Onco360 forward. His deep experience in healthcare and oncology make him the ideal CEO for Onco360. We are confident that, under his leadership, Onco360 will continue to fulfill its mission of transforming oncology pharmacy, now and in the future.”

Burt Zweigenhaft will continue to serve as the Company’s Vice Chairman and Chief Strategy Officer. In this capacity, Mr. Zweigenhaft will focus on key strategic initiatives and business development to further support the Company’s growth strategy.